Stockpolly
Search
Delisting risk
BTAI · NASDAQ · Biotechnology

BioXcel Therapeutics (BTAI)

Develops neuroscience therapies through a data-driven drug re-innovation model.

$0.1215
Pre-market+0.01 (+11.37%)
At close$0.1091(−20.36%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue001100000000
Cost of revenue110011000000
Gross profit0001−10000000
482024181410101614111010
Research & development2010118565109733
241013984665477
Selling & marketing500−100000000
General & administrative209131074665407
Other expenses400120000000
Operating income−48−20−24−17−15−10−10−16−14−10−10−10
−2−2−39203−3−17−2−3−5
Interest income111110000000
Interest expense334444444444
Other non-operating income−1−1−1−13−5−4−7−113−2−20
Income before tax−50−22−27−8−14−11−7−19−31−13−13−15
Net income from continuing operations−50−22−27−8−14−11−7−19−31−13−13−15
Net income−50−22−27−8−14−11−7−19−31−13−13−15
EPS, basic−$27.60−$12.09−$13.89−$3.30−$5.15−$3.57−$1.50−$2.45−$2.18−$1.03−$1.04−$1.21
EPS, diluted−$27.60−$12.09−$13.89−$3.30−$5.15−$3.57−$1.50−$2.45−$2.18−$1.03−$1.04−$1.21
Weighted average shares, basic2223335814121212
Weighted average shares, diluted2223335814121212
EBITDA−47−19−23−5−10−7−3−15−26−8−8−10
Depreciation & amortization000000000000
EBIT−47−19−23−5−10−7−3−15−27−8−8−10